Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492778 | 1.00 | CNR2 (0.40) | CNR2CES2CES1GAATBXAS1 | |
| SCHEMBL20213591 | 0.89 | CNR2 (0.43) | CNR2CES2CES1GAAMEN1 | |
| SCHEMBL30014826 | 0.89 | CNR2 (0.43) | CNR2CES2CES1GAAMEN1 | |
| SCHEMBL960872 | 0.83 | MEN1 (0.46) | TBXAS1MEN1KMT2A | |
| SCHEMBL2487911 | 0.83 | CNR2 (0.41) | CNR2CES2CES1GAAMEN1 | |
| SCHEMBL960617 | 0.82 | CES2 (0.41) | CES2CES1IDO1TDO2 | |
| SCHEMBL23412757 | 0.80 | CES2 (0.40) | CES2CES1TBXAS1 | |
| SCHEMBL2485641 | 0.80 | CES2 (0.40) | CES2CES1TBXAS1 | |
| SCHEMBL962850 | 0.80 | TBXAS1 (0.52) | TBXAS1SMN1; SMN2 | |
| SCHEMBL7705788 | 0.80 | CYSLTR2 (0.43) | CNR2CES2CES1GAATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315745-B | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3728262-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-11440915-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3728262-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111315745-A | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102356081-A | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-02-15 | — | — | CN | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | CNR2 1827/4885CES2 2899/4885CES1 2722/4885 |
| US-11440915-B2 | Triazolo-azepine derivatives | HUWE1, PSEN1, UPF1 | CNR2 2183/4885CES2 2986/4885CES1 2886/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | CNR2 2864/4885CES2 1310/4885CES1 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.